leisure time -WSS

leisure time

author：focus 2025-09-14 21:46:18 - browse：5526

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： What drug price negotiations mean for Medicare Part D

hotspot

WSS

Weighted lottery helped low

Lack of darker skin in textbooks, journals harms patients of color

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

ALS advocates say criticism of new drugs misses bigger picture

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

'Make People Better': The CRISPR babies story you probably don't know

focus

leisure time

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Drug repurposing or repositioning? The language matters

A strong 6.5

United colonoscopy coverage change 'may cost lives,' doctors say

House transparency, PBM reform bill gains bipartisan support

How to save PrEP access — and even expand it

Robert Kennedy Jr.'s presidential campaign attracts GOP

Sports medicine is finally prioritizing gender equality

Medicaid rebukes states for mistakenly disenrolling children

entertainment

Listen: Biogen's potential pivot, & Illumina's next chapter

NIH nominee Bertagnolli will get October confirmation hearing

A rare thyroid diagnosis led to unexpected, all

FDA seeking to stop procedures at two unregulated stem cell clinics

NIH nominee Bertagnolli will get October confirmation hearing

Ethical issues complicate the benefits of medical crowdfunding

hotspot

Wikipedia

hotspot

hotspot